aluates Reports

$ 0.0

Automative

ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-9I14521

Global ICAD Intracranial Atherosclerotic Disease Pathology Treatment Market Research Report 2023

BUY CHAPTERS

ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-9I14521

Report

October 2024

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Stryker

Balt

Terumo

MicroPort

Acandis GmbH

ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market Size

The global market for ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment was estimated to be worth US$ 190 million in 2023 and is forecast to a readjusted size of US$ 373.8 million by 2030 with a CAGR of 10.0% during the forecast period 2024-2030

ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market

Intracranial atherosclerotic disease is the progressive narrowing of the cerebral arteries within the skull (intracranial). The arteries that supply oxygen-enriched blood to the brain are the carotid arteries and the vertebral arteries. The circle of Willis is the area at the base of the brain that joins these arteries.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment by region & country, by Type, and by Application.

The ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment.

Market Segmentation

Scope of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market Report

Report Metric	Details
Report Name	ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market
Forecasted market size in 2030	US$ 373.8 million
CAGR	10.0%
Forecasted years	2024 - 2030
Segment by Type:	Stent PTA Balloon
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Stryker, Balt, TERUMO, MicroPort, Acandis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market size in 2030?

Ans: The ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market size in 2030 will be US$ 373.8 million.

Who are the main players in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market report?

Ans: The main players in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market are Stryker, Balt, TERUMO, MicroPort, Acandis

What are the Application segmentation covered in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market report?

Ans: The Applications covered in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market report?

Ans: The Types covered in the ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment - Market report are Stent, PTA Balloon

Recommended Reports

Cardiovascular & Cerebrovascular

Neurovascular Disorders

Neurological Diseases

1 Market Overview

1.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Product Introduction

1.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Size Forecast

1.3 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Trends & Drivers

1.3.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Industry Trends

1.3.2 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Drivers & Opportunity

1.3.3 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Challenges

1.3.4 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Players Revenue Ranking (2023)

2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue by Company (2019-2024)

2.3 Key Companies ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment

2.6 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Competitive Analysis

2.6.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Stent

3.1.2 PTA Balloon

3.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type

3.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, by Type (2019-2030)

3.2.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Other

4.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application

4.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, by Application (2019-2030)

4.2.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region

5.1.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2019-2024)

5.1.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2025-2030)

5.1.4 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

5.2.2 North America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

5.3.2 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

5.5.2 South America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value

6.3 United States

6.3.1 United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.3.2 United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.4.2 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.5.2 China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.6.2 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.7.2 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019-2030

6.9.2 India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Stryker

7.1.1 Stryker Profile

7.1.2 Stryker Main Business

7.1.3 Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

7.1.4 Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Stryker Recent Developments

7.2 Balt

7.2.1 Balt Profile

7.2.2 Balt Main Business

7.2.3 Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

7.2.4 Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Balt Recent Developments

7.3 TERUMO

7.3.1 TERUMO Profile

7.3.2 TERUMO Main Business

7.3.3 TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

7.3.4 TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 MicroPort Recent Developments

7.4 MicroPort

7.4.1 MicroPort Profile

7.4.2 MicroPort Main Business

7.4.3 MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

7.4.4 MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 MicroPort Recent Developments

7.5 Acandis

7.5.1 Acandis Profile

7.5.2 Acandis Main Business

7.5.3 Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

7.5.4 Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Acandis Recent Developments

8 Industry Chain Analysis

8.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Industrial Chain

8.2 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Model

8.5.2 Sales Channel

8.5.3 ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Stryker

Balt

Terumo

MicroPort

Acandis GmbH

List of Tables

Table 1. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Trends

Table 2. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Drivers & Opportunity

Table 3. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Challenges

Table 4. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Restraints

Table 5. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment

Table 10. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Stryker Basic Information List

Table 32. Stryker Description and Business Overview

Table 33. Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Business of Stryker (2019-2024)

Table 35. Stryker Recent Developments

Table 36. Balt Basic Information List

Table 37. Balt Description and Business Overview

Table 38. Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Business of Balt (2019-2024)

Table 40. Balt Recent Developments

Table 41. TERUMO Basic Information List

Table 42. TERUMO Description and Business Overview

Table 43. TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Business of TERUMO (2019-2024)

Table 45. TERUMO Recent Developments

Table 46. MicroPort Basic Information List

Table 47. MicroPort Description and Business Overview

Table 48. MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Business of MicroPort (2019-2024)

Table 50. MicroPort Recent Developments

Table 51. Acandis Basic Information List

Table 52. Acandis Description and Business Overview

Table 53. Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Business of Acandis (2019-2024)

Table 55. Acandis Recent Developments

Table 56. Key Raw Materials Lists

Table 57. Raw Materials Key Suppliers Lists

Table 58. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Downstream Customers

Table 59. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Distributors List

Table 60. Research Programs/Design for This Report

Table 61. Key Data Information from Secondary Sources

Table 62. Key Data Information from Primary Sources

Table 63. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Product Picture

Figure 2. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Report Years Considered

Figure 5. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Revenue in 2023

Figure 7. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Stent Picture

Figure 9. PTA Balloon Picture

Figure 10. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital

Figure 13. Product Picture of Clinic

Figure 14. Product Picture of Other

Figure 15. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 18. North America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

Figure 23. South America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 24. South America ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value (%), (2019-2030)

Figure 28. United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 30. United States ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 34. China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 35. China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 36. China ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. India ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Industrial Chain

Figure 50. ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Intracranial Atherosclerotic Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intracranial Aneurysm Treatment Market Insights Forecast to 2030

Global Cardiovascular and Cerebrovascular Disease Treatment Drugs Market Research Report 2024

Global Atherosclerosis Therapeutics Market Insights Forecast to 2030

Intracranial Stent System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Brain Ischemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intracranial Stents Market Research Report 2025

Global Cerebral Infarction Therapy Market Insights Forecast to 2030

Global Cerebrovascular Disease Market Research Report 2024

Global Balloon expanded Intracranial Stents Market Research Report 2024

Global Ischemic Neurointerventional Device Market Research Report 2025

Global Coronary Artery Disease Therapeutics Market Research Report 2024

Intrasaccular Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ischemic Cerebrovascular Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global AI Medical Imaging Software for Chronic Cerebrovascular Diseases Market Research Report 2024

Global Self expandable Intracranial Stents Market Research Report 2024

Global Peripheral Artery Disease Treatment Devices Market Research Report 2024

Global Diagnostics of Peripheral Arterial Disease Market Research Report 2025

Global Acute Ischemic Stroke Drugs Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions